NASDAQ:CELC Celcuity (CELC) Stock Price, News & Analysis $51.23 -3.37 (-6.17%) Closing price 04:00 PM EasternExtended Trading$52.25 +1.02 (+1.99%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Celcuity Stock (NASDAQ:CELC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Celcuity alerts:Sign Up Key Stats Today's Range$51.17▼$55.0050-Day Range$11.45▼$54.6052-Week Range$7.57▼$55.44Volume731,213 shsAverage Volume603,818 shsMarket Capitalization$2.17 billionP/E RatioN/ADividend YieldN/APrice Target$56.50Consensus RatingBuy Company Overview Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota. Read More Celcuity Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreCELC MarketRank™: Celcuity scored higher than 37% of companies evaluated by MarketBeat, and ranked 860th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingCelcuity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCelcuity has only been the subject of 4 research reports in the past 90 days.Read more about Celcuity's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Celcuity are expected to decrease in the coming year, from ($2.62) to ($3.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celcuity is -14.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celcuity is -14.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelcuity has a P/B Ratio of 48.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Celcuity's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.43% of the float of Celcuity has been sold short.Short Interest Ratio / Days to CoverCelcuity has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Celcuity has recently increased by 29.29%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCelcuity does not currently pay a dividend.Dividend GrowthCelcuity does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.43% of the float of Celcuity has been sold short.Short Interest Ratio / Days to CoverCelcuity has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Celcuity has recently increased by 29.29%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News Sentiment0.62 News SentimentCelcuity has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Celcuity this week, compared to 3 articles on an average week.Search Interest8 people have searched for CELC on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows7 people have added Celcuity to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,818,744.00 in company stock.Percentage Held by Insiders15.77% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Celcuity's insider trading history. Receive CELC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CELC Stock News HeadlinesCelcuity Inc.: Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review ProgramAugust 28 at 10:37 PM | finanznachrichten.deCelcuity stock jumps after FDA accepts gedatolisib NDA for reviewAugust 28 at 10:37 PM | za.investing.comMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.August 29 at 2:00 AM | The Oxford Club (Ad)Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review ProgramAugust 28 at 10:37 PM | markets.businessinsider.comCelcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review ProgramAugust 27 at 4:05 PM | globenewswire.comCelcuity, Inc. (NASDAQ:CELC) Receives $47.40 Consensus Target Price from AnalystsAugust 19, 2025 | americanbankingnews.comCelcuity price target raised to $66 from $50 at H.C. WainwrightAugust 18, 2025 | msn.comStifel Nicolaus Keeps Their Buy Rating on Celcuity (CELC)August 18, 2025 | theglobeandmail.comSee More Headlines CELC Stock Analysis - Frequently Asked Questions How have CELC shares performed this year? Celcuity's stock was trading at $13.09 at the beginning of 2025. Since then, CELC shares have increased by 291.9% and is now trading at $51.2960. How were Celcuity's earnings last quarter? Celcuity, Inc. (NASDAQ:CELC) posted its earnings results on Thursday, August, 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by $0.14. Read the conference call transcript. When did Celcuity IPO? Celcuity (CELC) raised $18 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO. Who are Celcuity's major shareholders? Top institutional shareholders of Celcuity include Soleus Capital Management L.P. (7.74%), Perceptive Advisors LLC (4.20%), Eventide Asset Management LLC (3.57%) and Saturn V Capital Management LP (3.05%). Insiders that own company stock include Richard Nigon, Richard E Buller and David Dalvey. View institutional ownership trends. How do I buy shares of Celcuity? Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Celcuity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celcuity investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and ServiceNow (NOW). Company Calendar Last Earnings8/14/2025Today8/29/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryHealthcare Current SymbolNASDAQ:CELC CIK1603454 Webwww.celcuity.com Phone(763) 392-0767FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for Celcuity$56.50 High Price Target$70.00 Low Price Target$30.00 Potential Upside/Downside+3.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($3.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$111.78 million Net MarginsN/A Pretax MarginN/A Return on Equity-150.07% Return on Assets-64.67% Debt Debt-to-Equity Ratio2.24 Current Ratio4.58 Quick Ratio4.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book52.00Miscellaneous Outstanding Shares42,430,000Free Float35,736,000Market Cap$2.32 billion OptionableOptionable Beta0.68 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CELC) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celcuity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.